Core Viewpoint - Masimo (MASI) is positioned well to potentially beat earnings estimates in its upcoming quarterly report, supported by a strong history of exceeding expectations in previous quarters [1]. Earnings Performance - Masimo has a solid track record of surpassing earnings estimates, with an average surprise of 14.18% over the last two quarters [2]. - In the last reported quarter, Masimo achieved earnings of $0.98 per share, exceeding the Zacks Consensus Estimate of $0.84 per share, resulting in a surprise of 16.67% [3]. - For the previous quarter, the company was expected to report earnings of $0.77 per share but delivered $0.86 per share, yielding a surprise of 11.69% [3]. Earnings Estimates and Predictions - Recent estimates for Masimo have been trending upward, indicating positive sentiment among analysts [4]. - The Zacks Earnings ESP for Masimo is currently positive at +4.05%, suggesting bullish expectations for near-term earnings [7]. - The combination of a positive Earnings ESP and a Zacks Rank of 1 (Strong Buy) indicates a high likelihood of another earnings beat [7]. Statistical Insights - Research indicates that stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [5]. - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [6]. Upcoming Events - Masimo's next earnings report is anticipated to be released on February 25, 2025 [7].

Group 1: Momentum Investing Overview - Momentum investing involves following a stock's recent trend, with the aim of buying high and selling higher, capitalizing on established price movements [1] - The Zacks Momentum Style Score helps define momentum characteristics, with Masimo (MASI) currently holding a Momentum Style Score of A [2] Group 2: Masimo's Performance Metrics - Masimo has a Zacks Rank of 2 (Buy), indicating strong potential for outperformance, especially for stocks rated 1 (Strong Buy) and 2 (Buy) with Style Scores of A or B [3] - Over the past week, MASI shares increased by 3.53%, outperforming the Zacks Medical - Instruments industry, which rose by 1.15% [5] - In the last quarter, MASI shares rose by 24.83%, and over the past year, they gained 40.86%, while the S&P 500 increased by only 3.62% and 26.55%, respectively [6] Group 3: Trading Volume and Earnings Outlook - The average 20-day trading volume for MASI is 391,651 shares, which serves as a bullish indicator when combined with rising stock prices [7] - In the past two months, two earnings estimates for MASI have increased, raising the consensus estimate from $4.00 to $4.04, with no downward revisions noted [9] Group 4: Conclusion - Given the strong performance metrics and positive earnings outlook, MASI is positioned as a 2 (Buy) stock with a Momentum Score of A, making it a compelling investment option [11]

Masimo Corporation (MASI) Preliminary Results and Guidance - Masimo announced preliminary revenues for Q4 2024 and full-year 2024, with shares gaining nearly 0.1% following the announcement [1] - Q4 2024 total revenues are estimated at $601 million, up 9% YoY on both reported and constant exchange rate (CER) basis, exceeding the Zacks Consensus Estimate of $594.6 million [2] - Healthcare revenues for Q4 2024 are estimated at $368 million (up 8% YoY reported, 9% CER), while Non-healthcare revenues are estimated at $232 million (up 11% YoY reported and CER) [2] - Full-year 2024 total revenues are estimated at $2,094 million, up 2% YoY reported and 3% CER, in line with the Zacks Consensus Estimate of $2.09 billion [4] - Healthcare revenues for 2024 are estimated at $1,395 million (up 9% YoY reported, 10% CER), while Non-healthcare revenues are estimated at $699 million (down 10% YoY reported, 9% CER) [5] - Adjusted EPS for 2024 is expected to exceed $4.10, surpassing the Zacks Consensus Estimate of $4.04 [5] Masimo's 2025 Guidance - Healthcare revenues for 2025 are estimated between $1,500 million and $1,530 million, representing 8% growth YoY reported and 11% CER [7] - Adjusted EPS for 2025 is expected to be in the range of $4.90-$5.10, above the Zacks Consensus Estimate of $4.49 [7] Business Segment Performance and Outlook - Non-healthcare revenues improved in Q4 2024, driven by a rebound in luxury consumer purchases and the housing market [8] - Masimo's core healthcare segment drove performance in Q3 2024, with robust growth in Healthcare revenues continuing into Q4 2024 [9] - Management is focusing on long-term growth by reallocating resources to fewer projects, concentrating on sizable market opportunities, and reducing spending in non-strategic areas [10] Stock Performance and Industry Comparison - Masimo's shares gained 28.4% between Sept 29 and Dec 28, 2024, outperforming the industry's 3.9% decline and the S&P 500's 4.8% gain [12] - Masimo currently carries a Zacks Rank 2 (Buy) [13] Other Top-Ranked Medical Stocks - Cardinal Health (CAH) has a Zacks Rank 2, with an estimated long-term growth rate of 10.5% and shares gaining 8.5% compared to the industry's 1.2% growth [14] - Cencora (COR) has a Zacks Rank 2, with an estimated long-term growth rate of 10.4% and shares gaining 0.9% against the industry's 14.4% decline [15] - DaVita (DVA) has a Zacks Rank 1, with an estimated long-term growth rate of 18.3% and shares losing 5.4% compared to the industry's 8.2% decline [17]

Price Target Changes - Goldman Sachs cut the price target for Bright Horizons Family Solutions Inc. (BFAM) from $162 to $142 while maintaining a Buy rating. The shares closed at $110.83 [1] - Rodman & Renshaw raised the price target for Viracta Therapeutics, Inc. (VIRX) from $3.5 to $0.25 but downgraded the stock from Buy to Neutral. The shares closed at $0.2370 [1] - Raymond James raised the price target for Masimo Corporation (MASI) from $170 to $194 while maintaining an Outperform rating. The shares closed at $171.02 [1] - Goldman Sachs slashed the price target for KinderCare Learning Companies, Inc. (KLC) from $41 to $35 while maintaining a Buy rating. The shares closed at $17.88 [1] - B of A Securities boosted the price target for MakeMyTrip Limited (MMYT) from $119 to $130 while maintaining a Buy rating. The shares settled at $116.21 [1]

Core Insights - The Medical Instruments industry is experiencing rapid advancements due to AI and predictive analytics, enhancing diagnostics, patient monitoring, and personalized treatment [1][2] - The adoption of generative AI (genAI) and digital therapeutics is expected to significantly impact the healthcare industry by 2025, improving early disease detection and operational efficiency [2][5] - Despite challenges such as geopolitical tensions and supply chain issues, companies like Masimo Corporation, Penumbra, and Veracyte are adapting well and seeing stock price increases [3] Industry Overview - The Zacks Medical - Instruments industry is fragmented, focusing on R&D across various therapeutic areas and utilizing AI for quick and accurate disease diagnosis and treatment [4] - Key trends include the rise of telemedicine, robotic-assisted surgeries, and advancements in 3D printing and nanomedicine [4] Trends Shaping the Industry - The genAI market in healthcare was valued at $1.8 billion in 2023 and is projected to grow at a CAGR of 33.2% from 2024 to 2032, driven by increasing demand for personalized treatment and advancements in AI technologies [5] - The diagnostics market is also expected to grow at a CAGR of 24.6% by 2034, indicating a significant shift towards AI applications in this area [5] M&A Activity - The industry is witnessing a robust M&A trend, with 168 deals worth $14.4 billion announced in Q3 2024, marking a 247% increase in value compared to the previous year [6] - Notable transactions include Johnson & Johnson's $13.1 billion acquisition of Shockwave Medical and Becton, Dickinson and Company's $4.2 billion purchase of Edwards Lifesciences' Critical Care division [6] Economic Context - The IMF projects real GDP growth of 3.2% for 2024 and 2025, with a decline in inflation expected by 2025 [7][8] - Despite these projections, risks remain due to geopolitical conflicts and potential financial market volatility [8] Industry Performance - The Zacks Medical Instruments industry has underperformed the S&P 500 but outperformed the broader sector, rising 7.7% over the past year [11] - The industry currently trades at a forward P/E of 32.16X, higher than the broader industry average of 20.63X and the S&P 500's 22.66X [13] Company Highlights - **Veracyte**: Expected 2024 sales of $443.9 million, a 22.9% increase from 2023, with a projected EPS of 38 cents, up 137.3% [17] - **Masimo**: Anticipated 2024 sales of $2.09 billion, a 1.9% rise, with an EPS estimate of $4.03, reflecting a 6.3% increase [20] - **Penumbra**: Projected 2024 sales of $1.19 billion, a 12.5% increase, with an EPS estimate of $2.81, up 34.5% from the previous year [24]

Masimo Corporation (MAMO) reported a GAAP earnings per share (EPS) of 18 cents, which was slightly lower than the 20 cents reported in the third quarter of 2023. However, the non-GAAP EPS for the third quarter of 2024 was 98 cents, showing an improvement from the 75 cents achieved in the same period of the prior year.  Total revenues for the quarter were $504.6 million, reflecting a year-over-year increase from $478.9 million in the third quarter of 2023. This was divided into healthcare revenues of $343.3 ...

Masimo Corporation (MASI) delivered adjusted earnings per share (EPS) of 98 cents in the third quarter of 2024, up 30.7% year over year. The figure beat the Zacks Consensus Estimate by 16.7%.The adjustments include acquired intangible asset amortization, and acquisitions, integrations, divestitures, and related costs, among others.GAAP EPS for the quarter was 18 cents, down 10% year over year.MASI’s Revenues in DetailMasimo registered revenues of $504.6 million in the third quarter, up 5.4% year over year o ...

Masimo Corporation (NASDAQ:MASI) Q3 2024 Earnings Conference Call November 5, 2024 4:30 PM ET Company Participants Eli Kammerman - VP of Business Development and IR Michelle Brennan - Interim CEO Micah Young - EVP and CFO Bilal Muhsin - COO Conference Call Participants Jason Bednar - Piper Sandler Marie Thibault - BTIG Michael Polark - Wolfe Research Frederick Wise - Stifel Matt Taylor - Jefferies Vik Chopra - Wells Fargo Michael Matson - Needham Jayson Bedford - Raymond James Operator Ladies and gentlemen, ...

Masimo (MASI) reported $504.6 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 5.4%. EPS of $0.98 for the same period compares to $0.63 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $502.58 million, representing a surprise of +0.40%. The company delivered an EPS surprise of +16.67%, with the consensus EPS estimate being $0.84.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ...

Masimo (MASI) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.84 per share. This compares to earnings of $0.63 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 16.67%. A quarter ago, it was expected that this medical technology company would post earnings of $0.77 per share when it actually produced earnings of $0.86, delivering a surprise of 11.69%.Over the last four quarters, th ...